Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
FBIOPDividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| June 30, 2024 | $0.20 | 2024-06-14 | 2024-06-15 |
| May 31, 2024 | $0.20 | 2024-05-14 | 2024-05-15 |
| April 30, 2024 | $0.20 | 2024-04-12 | 2024-04-15 |
| March 31, 2024 | $0.20 | 2024-03-14 | 2024-03-15 |
| February 29, 2024 | $0.20 | 2024-02-14 | 2024-02-15 |
Dividends Summary
- Consistent Payer: Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock has rewarded shareholders with 58 dividend payments over the past 6 years.
- Total Returned Value: Investors who held FBIOP shares during this period received a total of $15.23 per share in dividend income.
- Latest Payout: The most recent dividend of $0.20/share was paid 572 days ago, on June 30, 2024.
- Yield & Schedule: FBIOP currently pays dividends monthly with an annual yield of 18.44%.
- Dividend Growth: Since 2018, the dividend payout has decreased by 66.7%, from $0.59 to $0.20.
Company News
Fortress Biotech and its subsidiary Cyprium Therapeutics received a Complete Response Letter from the FDA regarding the New Drug Application for CUTX-101, citing manufacturing facility cGMP deficiencies, which negatively impacted the company's stock price.
Fortress Biotech's subsidiary Cyprium Therapeutics received a Complete Response Letter from the FDA for CUTX-101, a drug intended to treat Menkes disease. Sentynl Therapeutics, which assumed responsibility for the drug, plans to address manufacturing facility cGMP deficiencies and resubmit the New Drug Application.
Fortress Biotech announced the closing of the sale of its subsidiary Checkpoint Therapeutics to Sun Pharmaceutical Industries Limited. The transaction will generate approximately $28 million for Fortress and a 2.5% royalty on net sales of Checkpoint's FDA-approved drug UNLOXCYT.
Fortress Biotech, an innovative biopharmaceutical company, announced the FDA approval of its drug Emrosi for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway. The company also announced a strategic collaboration with Partex NV to accelerate asset identification and evaluation using Partex's proprietary A...
Mustang Bio, a clinical-stage biopharmaceutical company, announced the closing of a public offering of common stock and warrants, raising approximately $8 million. The company plans to use the proceeds for working capital and general corporate purposes.
